DUBLIN--(BUSINESS WIRE)--The "Primary Immune Deficiency (PID) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Primary Immune Deficiency (PID) development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Primary Immune Deficiency (PID) pipeline products by developmental stage, product type, molecule type, and administration route.
- The report provides a snapshot of the pipeline development for the Primary Immune Deficiency (PID)
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Primary Immune Deficiency (PID)
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Primary Immune Deficiency (PID)
- The report also covers the dormant and discontinued pipeline projects related to the Primary Immune Deficiency (PID)
- ADMA Biologics Inc
- Biotest AG
- Genethon SA
- GigaGen Inc
- GlaxoSmithKline Plc
- Green Cross Corp
- Novartis AG
- ProMetic Life Sciences Inc
- Shire Plc
- Taiga Biotechnologies Inc
- UCB SA
Key Topics Covered
1. Report Introduction
2. Primary Immune Deficiency (PID) Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wq3r54/primary_immune?w=4